Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative

M.A.S. Soares; L. Antunes; P. Redondo; M. Borges; R. Hermans; D. Patel; F. Grimson; R. Munro; C. Chaib; L. Lacoin; M. Daumont; J.R. Penrod; J.C. O’Donnell; M.J. Bento; F.R. Goncalves

Journal ArticleOPEN ACCESS

Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative

Soares M
Antunes L
Redondo P
et al.

Annals of Oncology (2019) 30 ii15-ii16

DOI: 10.1093/annonc/mdz070.003

N/ACitations

5Readers

Abstract

… Platinum-based chemotherapy, 72.9, 87.3. Non-platinum single agent, 4.5, 12.7. TKI (any), 22.6, 0.0. Erlotinib, 12.7, 0.0. Crizotinib, 2.3, 0.0. Gefitinib, 7.7, 0.0 … Non-platinum single agent, 59.8, 73.7. TKI (any), 24.4, 0.0. Erlotinib, 9.8, 0.0. Crizotinib, 11.0, 0.0. Other TKI, 3.6, 0.0 …

Cite

CITATION STYLE

APA

Soares, M. A. S., Antunes, L., Redondo, P., Borges, M., Hermans, R., Patel, D., … Goncalves, F. R. (2019). Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative. Annals of Oncology, 30, ii15–ii16. https://doi.org/10.1093/annonc/mdz070.003

Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative

Abstract

Cite

Register to see more suggestions